-
1.发明授权公开(公告)号：US09067871B2
公开(公告)日：2015-06-30
申请号：US14031265
申请日：2013-09-19
发明人： Wilhelm Amberg , Michael Ochse , Udo Lange , Andreas Kling , Berthold Behl , Wilfried Hornberger , Mario Mezler , Charles W. Hutchins
IPC分类号： A61K31/16 , C07C215/70 , C07C311/05 , C07C215/64 , C07C217/74 , C07C233/18 , C07C233/19 , C07C233/69 , C07C255/58 , C07C271/24 , C07C307/06 , C07C309/65 , C07C311/07 , C07C311/09 , C07C311/10 , C07C311/14 , C07C311/17 , C07C311/18 , C07C311/20 , C07C311/24 , C07C317/18 , C07C317/28 , C07D205/04 , C07D207/10 , C07D207/12 , C07D207/27 , C07D207/36 , C07D207/48 , C07D213/71 , C07D231/18 , C07D233/84 , C07D249/12 , C07D261/08 , C07D275/02 , C07D295/096 , C07D305/08 , C07D333/34 , C07D403/12 , C07F7/08 , C07D401/12 , C07D409/12
CPC分类号： C07C311/05 , C07C215/64 , C07C217/74 , C07C233/18 , C07C233/19 , C07C233/69 , C07C255/58 , C07C271/24 , C07C307/06 , C07C309/65 , C07C311/07 , C07C311/09 , C07C311/10 , C07C311/13 , C07C311/14 , C07C311/17 , C07C311/18 , C07C311/20 , C07C311/24 , C07C317/18 , C07C317/28 , C07C2601/02 , C07C2601/04 , C07C2602/10 , C07D205/04 , C07D207/09 , C07D207/10 , C07D207/12 , C07D207/27 , C07D207/36 , C07D207/48 , C07D213/71 , C07D231/18 , C07D233/84 , C07D249/12 , C07D261/08 , C07D265/30 , C07D275/02 , C07D295/096 , C07D295/135 , C07D305/08 , C07D333/34 , C07D401/12 , C07D403/12 , C07D409/12 , C07F7/081
摘要： The present invention relates to aminotetraline derivatives of the formula (I) or a physiologically tolerated salt thereof. The invention relates to pharmaceutical compositions comprising such aminotetraline derivatives, and the use of such aminotetraline derivatives for therapeutic purposes. The aminotetraline derivatives are GlyT1 inhibitors.
-
2.发明申请AMINOTETRALINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY 有权氨基嘌呤衍生物，含有它们的药物组合物及其在治疗中的使用公开(公告)号：US20140031331A1
公开(公告)日：2014-01-30
申请号：US14031265
申请日：2013-09-19
发明人： Wilhelm Amberg , Michael Ochse , Udo Lange , Andreas Kling , Berthold Behl , Wilfried Hornberger , Mario Mezler , Charles W. Hutchins
IPC分类号： C07C311/05 , C07D233/84 , C07D231/18 , C07D213/71 , C07D409/12 , C07D207/12 , C07D275/02 , C07D205/04 , C07D403/12 , C07D401/12 , C07C271/24 , C07D333/34
CPC分类号： C07C311/05 , C07C215/64 , C07C217/74 , C07C233/18 , C07C233/19 , C07C233/69 , C07C255/58 , C07C271/24 , C07C307/06 , C07C309/65 , C07C311/07 , C07C311/09 , C07C311/10 , C07C311/13 , C07C311/14 , C07C311/17 , C07C311/18 , C07C311/20 , C07C311/24 , C07C317/18 , C07C317/28 , C07C2601/02 , C07C2601/04 , C07C2602/10 , C07D205/04 , C07D207/09 , C07D207/10 , C07D207/12 , C07D207/27 , C07D207/36 , C07D207/48 , C07D213/71 , C07D231/18 , C07D233/84 , C07D249/12 , C07D261/08 , C07D265/30 , C07D275/02 , C07D295/096 , C07D295/135 , C07D305/08 , C07D333/34 , C07D401/12 , C07D403/12 , C07D409/12 , C07F7/081
摘要： The present invention relates to aminotetraline derivatives of the formula (I) or a physiologically tolerated salt thereof.The invention relates to pharmaceutical compositions comprising such aminotetraline derivatives, and the use of such aminotetraline derivatives for therapeutic purposes. The aminotetraline derivatives are GlyT1 inhibitors.
摘要翻译： 本发明涉及式（I）的氨基四氢化萘衍生物或其生理上耐受的盐。 本发明涉及包含这种氨基四氢化萘衍生物的药物组合物，以及这种氨基四氢化萘衍生物用于治疗目的的用途。 氨基四氢叶酸衍生物是GlyT1抑制剂。
-
公开(公告)号：US20200325153A1
公开(公告)日：2020-10-15
申请号：US16872279
申请日：2020-05-11
发明人： Andrew S. Judd , Aaron R. Kunzer , Chunqiu Lai , Andrew J. Souers , Gerard M. Sullivan , Zhi-Fu Tao , Jesse A. Teske , Anthony Mastracchio , Xilu Wang , Cheng Ji , Michael D. Wendt , Xiaohong Song , George A. Doherty , Katja Jantos , Wilfried Braje , Andreas Kling , Frauke Pohlki , Thomas D. Penning
IPC分类号： C07D495/16 , C07D495/18 , A61K45/06 , C07D495/22 , C07D491/18 , A61K31/519 , C07D491/22 , A61P35/00 , A61P35/02
摘要： The present disclosure provides for compounds of formula (I) wherein A2, A3, A4, A6, A7, A8, A15, RA, R5, R9, R10A, R10B, R11, R12, R13, R14, R16, W, X, and Y have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions, including cancer. Also provided are pharmaceutical compositions comprising compounds of formula (I).
-
公开(公告)号：US20190144465A1
公开(公告)日：2019-05-16
申请号：US15998789
申请日：2018-08-15
发明人： Andrew S. Judd , Aaron R. Kunzer , Chunqiu Lai , Andrew J. Souers , Gerard M. Sullivan , Zhi-Fu Tao , Jesse A. Teske , Anthony Mastracchio , Xilu Wang , Cheng Ji , Michael D. Wendt , Xiaohong Song , George A. Doherty , Katja Jantos , Wilfried Braje , Andreas Kling , Frauke Pohlki , Thomas D. Penning
IPC分类号： C07D495/16 , A61P35/02
摘要： The present disclosure provides for compounds of formula (I) wherein A2, A3, A4, A6, A7, A8, R15, RA, R5, R9, R10A, R10B, R11, R12, R13, R14, R16, W, X, and Y have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions, including cancer. Also provided are pharmaceutical compositions comprising compounds of formula (I).
-
公开(公告)号：US09840495B2
公开(公告)日：2017-12-12
申请号：US15106670
申请日：2014-12-19
发明人： Hervé Geneste , Wilfried Hornberger , Charles W. Hutchins , Katja Jantos , Andreas Kling , Loic Laplanche , Marcel Van Gaalen
IPC分类号： A01N43/00 , A61K31/00 , C07D401/14 , C07D401/04 , C07B59/00 , C07D405/14 , C07D491/107
CPC分类号： C07D401/14 , C07B59/002 , C07B2200/05 , C07D401/04 , C07D405/14 , C07D491/107
摘要： The present invention relates to novel substituted oxindole derivatives of formula (I) wherein the variables are as defined in the claims and description; to pharmaceutical compositions comprising them, and to their use for treatment of vasopressin-related disorders.
-
公开(公告)号：US09527811B2
公开(公告)日：2016-12-27
申请号：US14570996
申请日：2014-12-15
发明人： Helmut Mack , Andreas Kling , Katja Jantos , Achim Moeller , Wilfried Hornberger , Charles W. Hutchins
IPC分类号： C07D207/26 , C07D207/28 , C07D401/12 , C07D233/34 , C07D239/10 , C07D207/22 , C07D211/78 , C07D211/76 , C07D233/32 , C07D275/03 , C07D401/06 , C07D405/12 , C07D409/12 , C07D417/12 , C07D213/81
CPC分类号： C07D207/22 , C07D207/26 , C07D207/28 , C07D211/76 , C07D211/78 , C07D213/81 , C07D233/32 , C07D233/34 , C07D239/10 , C07D275/03 , C07D401/06 , C07D401/12 , C07D405/12 , C07D409/12 , C07D417/12
摘要： The present invention relates to novel carboxamide compounds and their use for the manufacture of a medicament. The carboxamide compounds are inhibitors of calpain (calcium dependant cysteine proteases). The invention therefore also relates to the use of these carboxamide compounds for treating a disorder associated with an elevated calpain activity.The carboxamide compounds are compounds of the general formula I in which R1, R2, R3a, R3b, R4, Q, Y, A and X have the meanings mentioned in the claims and the description, the tautomers thereof and the pharmaceutically suitable salts thereof. In particular, the compounds have the general formula Ia and Ib in which R1, r, R2b, R3a, R3b, R4, Y and X have the meanings mentioned in the claims, including the tautomers thereof and the pharmaceutically suitable salts thereof. Of these compounds those are preferred wherein Y is a moiety CH2—CH2, CH2—CH2—CH2, N(Ry#)—CH2, N(Ry#)—CH2—CH2 or CH═CH—CH═, each optionally having 1 or 2H-atoms replaced with identical or different radicals Ry, wherein Ry and Ry# have the meanings mentioned in the claims.
-
公开(公告)号：US09475782B2
公开(公告)日：2016-10-25
申请号：US13683296
申请日：2012-11-21
发明人： Astrid Netz , Wilhelm Amberg , Udo Lange , Michael Ochse , Charles W. Hutchins , Francisco-Xavier Garcia-Ladona , Wolfgang Wernet , Andreas Kling
IPC分类号： C07D277/48 , C07D277/82 , C07D333/36 , C07D263/48 , C07D277/60 , C07D235/30 , C07D513/04 , C07D417/12 , C07D417/04 , C07D231/56 , C07D237/22 , C07D249/14 , C07D261/14 , C07D263/28 , C07D285/08 , C07D285/135
CPC分类号： C07D277/48 , C07D231/56 , C07D235/30 , C07D237/22 , C07D249/14 , C07D261/14 , C07D263/28 , C07D263/48 , C07D277/60 , C07D277/82 , C07D285/08 , C07D285/135 , C07D333/36 , C07D417/04 , C07D417/12 , C07D513/04
摘要： The present invention relates to guanidine compounds of the general formula I corresponding enantiomeric, diastereomeric and/or tautomeric forms thereof as well as pharmaceutically acceptable salts thereof. The present compound further relates to the use of guanidine compounds as binding partners for 5-HT5 receptors for the treatment of diseases which are modulated by a 5-HT5 receptor activity, in particular for the treatment of neurodegenerative and neuropsychiatric disorders as well as the associated signs, symptoms and dysfunctions.
-
8.发明申请OXINDOLE DERIVATIVES CARRYING AN OXETANE SUBSTITUENT AND USE THEREOF FOR TREATING VASOPRESSIN-RELATED DISEASES 审中-公开携带OXETANE取代物的OXINDOLE衍生物及其用于治疗相关疾病的用途公开(公告)号：US20160168135A1
公开(公告)日：2016-06-16
申请号：US15050264
申请日：2016-02-22
发明人： Katja Jantos , Wilfried Braje , Hervé Geneste , Andreas Kling , Liliane Unger , Berthold Behl , Marcel van Gaalen , Wilfried Hornberger , Loic Laplanche , Silke Weber
IPC分类号： C07D405/14 , C07D487/08
CPC分类号： C07D405/14 , C07D487/08
摘要： The present invention relates to novel substituted oxindole derivatives, pharmaceutical compositions comprising them, and their use for the treatment of vasopressin-related disorders.
摘要翻译： 本发明涉及新型取代的羟基吲哚衍生物，包含它们的药物组合物及其用于治疗加压素相关病症的用途。
-
公开(公告)号：US20230399340A1
公开(公告)日：2023-12-14
申请号：US18046011
申请日：2022-10-12
发明人： Wilfried Braje , George Doherty , Katja Jantos , Cheng Ji , Andrew Judd , Aaron Kunzer , Anthony Mastracchio , Xiaohong Song , Andrew Souers , Gerard Sullivan , Zhi-Fu Tao , Chunqiu Lai , Andreas Kling , Frauke Pohlki , Jesse Teske , Michael Wendt , Patrick Brady , Xilu Wang , Thomas Penning , Michael Michaelides
IPC分类号： C07D495/16 , A61P35/00 , C07D519/00
CPC分类号： C07D495/16 , A61P35/00 , C07D519/00
摘要： The present disclosure provides for compounds of Formula (I)
wherein A2, A3, A4, A6, A7, A8, A15, RA, R5, R9, R10A, R10B, R11, R12, R13, R14, R16, W, X, and Y have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions, including cancer. Also provided are pharmaceutical compositions comprising compounds of Formula (I).-
公开(公告)号：US20230183261A1
公开(公告)日：2023-06-15
申请号：US17649906
申请日：2022-02-03
发明人： Andrew S. Judd , Aaron R. Kunzer , Chunqiu Lai , Andrew J. Souers , Gerard M. Sullivan , Zhi-Fu Tao , Jesse A. Teske , Anthony Mastracchio , Xilu Wang , Cheng Ji , Michael D. Wendt , Xiaohong Song , George A. Doherty , Katja Jantos , Wilfried Braje , Andreas Kling , Frauke Pohlki , Thomas D. Penning
IPC分类号： C07D495/16 , C07D495/18 , A61K45/06 , C07D495/22 , C07D491/18 , A61K31/519 , C07D491/22 , A61P35/00 , A61P35/02
CPC分类号： C07D495/16 , C07D495/18 , A61K45/06 , C07D495/22 , C07D491/18 , A61K31/519 , C07D491/22 , A61P35/00 , A61P35/02
摘要： The present disclosure provides for compounds of formula (I)
wherein A2, A3, A4, A6, A7, A8, A15, RA, R5, R9, R10A, R10B, R11, R12, R13, R14, R16, W, X, and Y have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions, including cancer. Also provided are pharmaceutical compositions comprising compounds of formula (I).
-
-
-
-
-
-
-
-
-
搜索结果
36 条记录 (耗时 0.045 秒)
